ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS MARKET ANALYSIS

Acute Bacterial Skin And Skin Structure Infections Market, By Drug Type (Oral & Parenteral Antibiotics and Topical Antibiotics), By Infection Type (Hospital Acquired ABSSSI and Community Acquired ABSSSI), By Route of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In July 2021, AbbVie, Inc., a biopharmaceutical company, announced that the U.S. Food and Drug Administration had approved DALVANCE (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients. DALVANCE is the first single-dose option administered as a 30-minute intravenous (IV) infusion for the treatment of ABSSSI caused by designated susceptible Gram-positive bacteria in pediatric patients, including infections caused by methicillin-resistant Staphylococcus aureus (MRSA).
In March 2021, Melinta Therapeutics LLC, a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved KIMYRSA (oritavancin) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA).